1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Blow For Janssen As England's NICE Rejects Depression Spray Spravato

Draft Guidance Out For Consultation Until 18 February

 
• By Neena Brizmohun

Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.

Blurred_Woman_Depression
NICE says Spravato should not be used on the NHS for patients with depression • Source: Shutterstock

NICE, the health technology appraisal body for England, has issued preliminary guidance rejecting Janssen's nasal spray Spravato (esketamine) for patients with treatment-resistant depression (TRD).

Uncertainties over clinical and cost effectiveness have resulted in NICE recommending against Spravato’s use on the National Health Service, according to the draft guidance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.